The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...

Descrición completa

Detalles Bibliográficos
Main Authors: Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl
Formato: Artigo
Idioma:English
Publicado: BMC 2025-01-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Acceso en liña:https://doi.org/10.1186/s12906-025-04753-w